| scholarly article | Q13442814 |
| P50 | author | Timothy Synold | Q78536675 |
| P2093 | author name string | Paul Frankel | |
| Yuan Chen | |||
| Marwan Fakih | |||
| Jun Gong | |||
| Daneng Li | |||
| Dean Lim | |||
| Gagandeep Singh | |||
| Vincent Chung | |||
| Kurt Melstrom | |||
| May Cho | |||
| Stephen Sentovich | |||
| Joseph Chao | |||
| Eloise Luevanos | |||
| P2860 | cites work | Granulomatous nephritis and dermatitis in a patient with BRAF V600E mutant metastatic melanoma treated with dabrafenib and trametinib. | Q54237366 |
| A phase I study of binimetinib (MEK162) in Japanese patients with advanced solid tumors. | Q55025521 | ||
| Reintroduction of Oxaliplatin Is Associated With Improved Survival in Advanced Colorectal Cancer | Q59901665 | ||
| Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer | Q24604601 | ||
| MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study | Q27852083 | ||
| New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) | Q28131668 | ||
| Cancer statistics, 2016 | Q29547383 | ||
| Clinical pharmacokinetics of oxaliplatin: a critical review | Q33898003 | ||
| A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. | Q34282412 | ||
| ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy | Q38294273 | ||
| Metastatic colorectal cancer: current state and future directions | Q38445676 | ||
| p38 Mitogen-activated protein kinase signaling, ERCC1 expression, and viability of lung cancer cells from never or light smoker patients | Q39380148 | ||
| Cisplatin regulates the MAPK kinase pathway to induce increased expression of DNA repair gene ERCC1 and increase melanoma chemoresistance | Q39458583 | ||
| Cisplatin treatment of primary and metastatic epithelial ovarian carcinomas generates residual cells with mesenchymal stem cell-like profile. | Q39535066 | ||
| Epidermal growth factor and ionizing radiation up-regulate the DNA repair genes XRCC1 and ERCC1 in DU145 and LNCaP prostate carcinoma through MAPK signaling | Q40663164 | ||
| Cisplatin-induced activation of mitogen-activated protein kinases in ovarian carcinoma cells: inhibition of extracellular signal-regulated kinase activity increases sensitivity to cisplatin | Q40951146 | ||
| Dabrafenib and trametinib activity in a patient with BRAF V600E mutated and microsatellite instability high (MSI-H) metastatic endometrial cancer | Q41099951 | ||
| MAPK dependence of DNA damage repair: ionizing radiation and the induction of expression of the DNA repair genes XRCC1 and ERCC1 in DU145 human prostate carcinoma cells in a MEK1/2 dependent fashion | Q42512056 | ||
| OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR study | Q46900220 | ||
| Assessment of the In Vivo Activity of PI3K and MEK Inhibitors in Genetically Defined Models of Colorectal Cancer. | Q53410679 | ||
| P433 | issue | 45 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | colorectal cancer | Q188874 |
| phase I clinical trial | Q5452194 | ||
| metastatic colon cancer | Q108566365 | ||
| P304 | page(s) | 79750-79760 | |
| P577 | publication date | 2017-07-18 | |
| P1433 | published in | Oncotarget | Q1573155 |
| P1476 | title | A phase I clinical trial of binimetinib in combination with FOLFOX in patients with advanced metastatic colorectal cancer who failed prior standard therapy | |
| P478 | volume | 8 |
| Q53705974 | BRAF and MEK Inhibitors: Use and Resistance in BRAF-Mutated Cancers. | cites work | P2860 |
Search more.